^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Campath (alemtuzumab) (CD52 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:…CLL/SLL without del(17p)/TP53 mutation...Other recommended regimens...alemtuzumab ± rituximab
